当前位置： SCI文献检索 > NEURO-ONCOLOGY期刊下所有文献 > Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

Abstract：

BACKGROUND:Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitrone compound OKN-007, a disulfonyl derivative of α-phenyl-tert-butyl nitrone. METHODS:MRI was used to assess tumor volumes in F98 and U87 gliomas, and bioluminescence imaging was used to measure tumor volumes in F98 gliomas encoded with the luciferase gene (F98(luc)). Immunohistochemistry was used to assess angiogenesis (vascular endothelial growth factor [VEGF] and microvessel density [MVD]), cell differentiation (carbonic anhydrase IX [CA-IX]), hypoxia (hypoxia-inducible factor-1α [HIF-1α]), cell proliferation (glucose transporter 1 [Glut-1] and MIB-1), proliferation index, and apoptosis (cleaved caspase 3) markers in F98 gliomas. VEGF, CA-IX, Glut-1, HIF-1α, and cleaved caspase 3 were assessed in U87 gliomas. RESULTS:Animal survival was found to be significantly increased (P < .001 for F98, P < .01 for U87) in the group that received OKN-007 treatment compared with the untreated groups. After MRI detection of F98 gliomas, OKN-007, administered orally, was found to decrease tumor growth (P < .05). U87 glioma volumes were found to significantly decrease (P < .05) after OKN-007 treatment, compared with untreated animals. OKN-007 administration resulted in significant decreases in tumor hypoxia (HIF-1α [P < .05] in both F98 and U87), angiogenesis (MVD [P < .05], but not VEGF, in F98 or U87), and cell proliferation (Glut-1 [P < .05 in F98, P < .01 in U87] and MIB-1 [P < .01] in F98) and caused a significant increase in apoptosis (cleaved caspase 3 [P < .001 in F98, P < .05 in U87]), compared with untreated animals. CONCLUSIONS:OKN-007 may be considered as a promising therapeutic addition or alternative for the treatment of aggressive human gliomas.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Towner RA,Gillespie DL,Schwager A,Saunders DG,Smith N,Njoku CE,Krysiak RS 3rd,Larabee C,Iqbal H,Floyd RA,Bourne DW,Abdullah O,Hsu EW,Jensen RL

doi

10.1093/neuonc/nos337

subject

Has Abstract

pub_date

2013-03-01 00:00:00

pages

330-40

issue

3

eissn

1522-8517

issn

1523-5866

pii

nos337

journal_volume

15

pub_type

杂志文章

相关文献

NEURO-ONCOLOGY文献大全
  • Increases in the number of brain metastases detected at frame-fixed, thin-slice MRI for gamma knife surgery planning.

    abstract：:For gamma knife planning, 2.4-mm-slice MRIs are taken under rigid frame fixation, so tiny tumors become visible. This study evaluated differences in the numbers of brain metastases between conventional contrast-enhanced MRI (6 ± 1 mm slice thickness) taken before patient referral and contrast-enhanced MRI for gamma kn...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noq084

    authors： Nagai A,Shibamoto Y,Mori Y,Hashizume C,Hagiwara M,Kobayashi T

    更新日期：2010-11-01 00:00:00

  • Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

    abstract：BACKGROUND:No more than half of patients with neurofibromatosis type 1 (NF1)-associated optic pathway gliomas (OPGs) develop vision loss. Prospectively identifying those who will require therapy remains challenging, because no reliable factors have yet been identified that predict future vision loss. To determine wheth...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not068

    authors： de Blank PM,Berman JI,Liu GT,Roberts TP,Fisher MJ

    更新日期：2013-08-01 00:00:00

  • DNA repair after irradiation in glioma cells and normal human astrocytes.

    abstract：:We examined DNA damage responses and repair in four human glioma cell lines (A7, U87, T98G, and U373) and normal human astrocytes (NHAs) after clinically relevant radiation doses to establish whether we could identify differences among them that might suggest new approaches to selective radiosensitization. We used pho...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2007-030

    authors： Short SC,Martindale C,Bourne S,Brand G,Woodcock M,Johnston P

    更新日期：2007-10-01 00:00:00

  • An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013.

    abstract：BACKGROUND:Primary central nervous system tumors (PCNST) among adolescents and young adults (AYA, 15-39 y) have rarely been reported. We present a nationwide report of PCNST histologically confirmed in the French AYA population between 2008 and 2013. METHODS:Patients were identified through the French Brain Tumor Data...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noz227

    authors： Ng S,Zouaoui S,Bessaoud F,Rigau V,Roux A,Darlix A,Bauchet F,Mathieu-Daudé H,Trétarre B,Figarella-Branger D,Pallud J,Frappaz D,Roujeau T,Bauchet L

    更新日期：2020-06-09 00:00:00

  • High failure rate in spinal ependymomas with long-term follow-up.

    abstract：:Data on spinal ependymomas are sparse, and prognostic factors remain controversial. The primary aim of this study is to review a historical cohort, with large patient numbers and long follow-up, and provide estimates of time to progression (TTP) and survival after progression. As a secondary aim, we assess the effects...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/S1152851704001231

    authors： Gomez DR,Missett BT,Wara WM,Lamborn KR,Prados MD,Chang S,Berger MS,Haas-Kogan DA

    更新日期：2005-07-01 00:00:00

  • Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007.

    abstract：:An increase in the incidence of CNS tumors has been observed in many countries in the last decades. The reality of this trend has been much debated, as it has happened during a period when computer-assisted tomography and MRI have dramatically improved the detection of these tumors. The Gironde CNS Tumor Registry prov...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nor120

    authors： Baldi I,Gruber A,Alioum A,Berteaud E,Lebailly P,Huchet A,Tourdias T,Kantor G,Maire JP,Vital A,Loiseau H,Gironde TSNC Registry Group.

    更新日期：2011-12-01 00:00:00

  • An NF-κB signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells.

    abstract：Background:While recent genome-wide association studies have suggested novel low-grade glioma (LGG) stratification models based on a molecular classification, we explored the potential clinical utility of patient-derived cells. Specifically, we assayed glioma-associated stem cells (GASC) that are patient-derived and re...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nox234

    authors： Ius T,Ciani Y,Ruaro ME,Isola M,Sorrentino M,Bulfoni M,Candotti V,Correcig C,Bourkoula E,Manini I,Pegolo E,Mangoni D,Marzinotto S,Radovic S,Toffoletto B,Caponnetto F,Zanello A,Mariuzzi L,Di Loreto C,Beltrami AP,Pia

    更新日期：2018-05-18 00:00:00

  • Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

    abstract：BACKGROUND:Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classification-however, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinico...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not125

    authors： Laxton RC,Popov S,Doey L,Jury A,Bhangoo R,Gullan R,Chandler C,Brazil L,Sadler G,Beaney R,Sibtain N,King A,Bodi I,Jones C,Ashkan K,Al-Sarraj S

    更新日期：2013-12-01 00:00:00

  • Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis.

    abstract：BACKGROUND:Optimal extent of surgical resection (EOR) of high-grade gliomas (HGGs) remains uncertain in the elderly given the unclear benefits and potentially higher rates of mortality and morbidity associated with more extensive degrees of resection. METHODS:We undertook a meta-analysis according to a predefined prot...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,meta分析,评审

    doi：10.1093/neuonc/nou349

    authors： Almenawer SA,Badhiwala JH,Alhazzani W,Greenspoon J,Farrokhyar F,Yarascavitch B,Algird A,Kachur E,Cenic A,Sharieff W,Klurfan P,Gunnarsson T,Ajani O,Reddy K,Singh SK,Murty NK

    更新日期：2015-06-01 00:00:00

  • Role of CX3CR1 signaling in malignant transformation of gliomas.

    abstract：BACKGROUND:Chemokine signaling may contribute to progression of low-grade gliomas (LGGs) by altering tumor behavior or impacting the tumor microenvironment. In this study, we investigated the role of CX3C chemokine receptor 1 (CX3CR1) signaling in malignant transformation of LGGs. METHODS:Ninety patients with LGGs wer...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noaa075

    authors： Lee S,Latha K,Manyam G,Yang Y,Rao A,Rao G

    更新日期：2020-10-14 00:00:00

  • Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.

    abstract：:PDGFRA is a critical gene in glioma biology. Similar to EGFR, PDGFRA has been shown to be overexpressed, amplified, mutated, or truncated in gliomas, particularly glioblastomas. In addition, PDGFRA has been recently shown to be rearranged in glioblastoma. However, the frequency, cooccurrence, and clinical value of PDG...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nos217

    authors： Alentorn A,Marie Y,Carpentier C,Boisselier B,Giry M,Labussière M,Mokhtari K,Hoang-Xuan K,Sanson M,Delattre JY,Idbaih A

    更新日期：2012-11-01 00:00:00

  • The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

    abstract：BACKGROUND:Genetic and epigenetic profiling of glioblastomas has provided a comprehensive list of altered cancer genes of which only O(6)-methylguanine-methyltransferase (MGMT) methylation is used thus far as a predictive marker in a clinical setting. We investigated the prognostic significance of genetic and epigeneti...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou005

    authors： Molenaar RJ,Verbaan D,Lamba S,Zanon C,Jeuken JW,Boots-Sprenger SH,Wesseling P,Hulsebos TJ,Troost D,van Tilborg AA,Leenstra S,Vandertop WP,Bardelli A,van Noorden CJ,Bleeker FE

    更新日期：2014-09-01 00:00:00

  • Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis.

    abstract：Background:Children with brain tumors treated with cranial radiation therapy (RT) often exhibit cognitive late effects, commonly associated with reduced white matter (WM) volume and decreased neurogenesis. The impact of radiation damage in particular regions or tissues on brain development as a whole has not been eluci...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nox211

    authors： Beera KG,Li YQ,Dazai J,Stewart J,Egan S,Ahmed M,Wong CS,Jaffray DA,Nieman BJ

    更新日期：2018-05-18 00:00:00

  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

    abstract：BACKGROUND:RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM). This study investigated whether early posttreatment progression on FLAIR or postcontrast MRI assessed by central reading predicts overall survival (OS). METHODS:O...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1093/neuonc/not049

    authors： Boxerman JL,Zhang Z,Safriel Y,Larvie M,Snyder BS,Jain R,Chi TL,Sorensen AG,Gilbert MR,Barboriak DP

    更新日期：2013-07-01 00:00:00

  • Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas.

    abstract：:The homeobox transcription factor OTX2 plays an essential role during embryonic brain development. It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs). Retinoic acids (RAs) can suppress OTX2 expression and inhibit MB gr...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nop062

    authors： Bai R,Siu IM,Tyler BM,Staedtke V,Gallia GL,Riggins GJ

    更新日期：2010-07-01 00:00:00

  • A low percentage of metastases in deep brain and temporal lobe structures.

    abstract：BACKGROUND:Whole-brain radiotherapy (WBRT) in patients with brain metastases (BM) is associated with neurocognitive decline. Given its crucial role in learning and memory, efforts to mitigate this toxicity have mostly focused on sparing radiation to the hippocampus. We hypothesized that BM are not evenly distributed ac...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noz023

    authors： Yanagihara TK,McFaline-Figueroa JR,Giacalone NJ,Lee AW,Soni V,Hwang ME,Hsieh KT,Saraf A,Wu CC,Yang D,Wen PY,Ashamalla H,Aizer AA,Wang TJC,Huang RY

    更新日期：2019-05-06 00:00:00

  • A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.

    abstract：:Background Nuclear factor IA (NFIA), a transcription factor and essential regulator in embryonic glial development, is highly expressed in human glioblastoma (GBM) compared with normal brain, but its contribution to GBM and cancer pathogenesis is unknown. Here we demonstrate a novel role for NFIA in promoting growth a...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/not167

    authors： Lee JS,Xiao J,Patel P,Schade J,Wang J,Deneen B,Erdreich-Epstein A,Song HR

    更新日期：2014-01-01 00:00:00

  • A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

    abstract：BACKGROUND:Both the epidermal growth factor receptor and vascular endothelial growth factor pathways are frequently overexpressed in glioblastoma multiforme. This study combined bevacizumab, a vascular endothelial growth factor inhibitor, and erlotinib, an epidermal growth factor receptor inhibitor, with standard radia...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nou029

    authors： Clarke JL,Molinaro AM,Phillips JJ,Butowski NA,Chang SM,Perry A,Costello JF,DeSilva AA,Rabbitt JE,Prados MD

    更新日期：2014-07-01 00:00:00

  • Paraneoplastic chorea: case study with autopsy confirmation.

    abstract：:A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/4.3.192

    authors： Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

    更新日期：2002-07-01 00:00:00

  • Cisplatin-induced peripheral neuropathy is associated to neuronal senescence-like response.

    abstract：BACKGROUND:Cisplatin-Induced Peripheral Neuropathy (CIPN) is a frequent serious dose-dependent adverse event that can determine dosage limitations for cancer treatment. CIPN severity correlates with the amount of platinum detected in sensory neurons of the dorsal root ganglia (DRG). However, the exact pathophysiology o...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noaa151

    authors： Calls A,Torres-Espin A,Navarro X,Yuste VJ,Udina E,Bruna J

    更新日期：2020-06-29 00:00:00

  • Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

    abstract：:Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noq170

    authors： Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

    更新日期：2011-01-01 00:00:00

  • Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma.

    abstract：:Malignant gliomas are the most common and lethal primary intracranial tumors. To date, no reliable biomarkers for the detection and risk stratification of gliomas have been identified. Recently, we demonstrated significant levels of microRNAs (miRNAs) to be present in cerebrospinal fluid (CSF) samples from patients wi...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nor169

    authors： Baraniskin A,Kuhnhenn J,Schlegel U,Maghnouj A,Zöllner H,Schmiegel W,Hahn S,Schroers R

    更新日期：2012-01-01 00:00:00

  • Racial differences in primary central nervous system lymphoma incidence and survival rates.

    abstract：:To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma (PCNSL), NCI Surveillance, Epidemiology, and End Results (SEER) program data from 1992 to 2002 were queried. Data were substratified by age (20-49 years vs. 50 or above) and race (White, Black,...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2008-103

    authors： Pulido JS,Vierkant RA,Olson JE,Abrey L,Schiff D,O'Neill BP

    更新日期：2009-06-01 00:00:00

  • EANO guidelines for the diagnosis and treatment of ependymal tumors.

    abstract：:Ependymal tumors are rare CNS tumors and may occur at any age, but their proportion among primary brain tumors is highest in children and young adults. Thus, the level of evidence of diagnostic and therapeutic interventions is higher in the pediatric compared with the adult patient population.The diagnosis and disease...

    journal_title：Neuro-oncology

    pub_type： 杂志文章,评审

    doi：10.1093/neuonc/nox166

    authors： Rudà R,Reifenberger G,Frappaz D,Pfister SM,Laprie A,Santarius T,Roth P,Tonn JC,Soffietti R,Weller M,Moyal EC

    更新日期：2018-03-27 00:00:00

  • Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.

    abstract：:Karenitecin is a highly lipophilic camptothecin analogue with a lactone ring that is relatively resistant to inactivating hydrolysis under physiologic conditions. This phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) of karenitecin in adults with recurrent malignant glioma (MG), to de...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2008-030

    authors： Grossman SA,Carson KA,Phuphanich S,Batchelor T,Peereboom D,Nabors LB,Lesser G,Hausheer F,Supko JG,New Approaches to Brain Tumor Therapy CNS Consortium.

    更新日期：2008-08-01 00:00:00

  • Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.

    abstract：:We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 199...

    journal_title：Neuro-oncology

    pub_type： 临床试验,杂志文章

    doi：10.1093/neuonc/2.1.22

    authors： Levin VA,Lamborn K,Wara W,Davis R,Edwards M,Rabbitt J,Malec M,Prados MD

    更新日期：2000-01-01 00:00:00

  • PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

    abstract：:We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1215/15228517-2009-003

    authors： Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

    更新日期：2009-12-01 00:00:00

  • Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

    abstract：BACKGROUND:Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular s...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noaa117

    authors： Eckel-Passow JE,Drucker KL,Kollmeyer TM,Kosel ML,Decker PA,Molinaro AM,Rice T,Praska CE,Clark L,Caron A,Abyzov A,Batzler A,Song JS,Pekmezci M,Hansen HM,McCoy LS,Bracci PM,Wiemels J,Wiencke JK,Francis S,Burns TC,

    更新日期：2020-11-26 00:00:00

  • Understanding brain penetrance of anticancer drugs.

    abstract：:This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/noy018

    authors： Levin VA,Ellingson BM

    更新日期：2018-04-09 00:00:00

  • Late relapse in primary central nervous system lymphoma: clonal persistence.

    abstract：:Recurrence of primary central nervous system lymphoma (PCNSL) after initial diagnosis and treatment occurs within 2 years in most patients, and relapse after 5 years is rare. We evaluated late relapse in our PCNSL population. We identified 10 patients from our database of 378 patients (268 achieved a complete response...

    journal_title：Neuro-oncology

    pub_type： 杂志文章

    doi：10.1093/neuonc/nor014

    authors： Nayak L,Hedvat C,Rosenblum MK,Abrey LE,DeAngelis LM

    更新日期：2011-05-01 00:00:00